Clinical trial
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
NCT00001830 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001830 |
|---|---|
| Title | Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants |
| Official title | Pilot Study of Donor Th2 Cells for the Prevention of Graft-Versus-Host Disease in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hodgkin's Disease, Multiple Myeloma, Non Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Th2 cells in allo HSCTT, Th2 Cells |
| Enrollment | 110 |
| Start date | Jul 20, 1999 |
| Completion | May 19, 2015 |
| First posted | Nov 4, 1999 |
| Last update posted | Jul 5, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: